RFL
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Rafael Holdings, Inc. (RFL) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Real Estate sector peers. Its strongest pillar is Momentum (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | F (0.0) | F (0.5) | C (2.5) | C+ (2.8) | C (2.4) | D+ (1.6) |
| 2026-11-07 | F (0.0) | F (0.6) | B (3.2) | C+ (2.8) | C (2.4) | D+ (1.8) |
| 2026-10-31 | F (0.0) | F (0.2) | C+ (2.5) | C+ (2.7) | C (2.4) | D+ (1.6) |
| 2026-10-24 | F (0.0) | F (0.2) | C+ (2.5) | B (3.2) | C (2.4) | D+ (1.7) |
| 2026-10-17 | F (0.0) | F (0.2) | C+ (2.5) | B (3.3) | C (2.4) | D+ (1.7) |